INBX Inhibrx Biosciences, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A.
19:11
Jan 30
Jan 30
07:29
Jan 26
Jan 26
Inhibrx's poor quality and rising valuation concern
The author takes a negative view of Inhibrx Biosciences, listing it among bad biotechs that are getting expensive, though not too expensive yet. His broader recommendation to short on valuation targets only the most stretched names. He provides no additional Inhibrx-specific rationale and discloses no short position.
About INBX Investor Commentary
Across the available history and selected sources, Buzzberg tracks INBX (Inhibrx Biosciences, Inc.) across 1 sources: 1 bullish vs 1 bearish calls from 1 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 11 total trade ideas tracked. Past 7 days, before deduplication: 5 other directions. Latest voices: seedy19tron.